CA2634670A1 - Method of identifying compounds useful to treat neuronal degenerative diseases - Google Patents

Method of identifying compounds useful to treat neuronal degenerative diseases Download PDF

Info

Publication number
CA2634670A1
CA2634670A1 CA002634670A CA2634670A CA2634670A1 CA 2634670 A1 CA2634670 A1 CA 2634670A1 CA 002634670 A CA002634670 A CA 002634670A CA 2634670 A CA2634670 A CA 2634670A CA 2634670 A1 CA2634670 A1 CA 2634670A1
Authority
CA
Canada
Prior art keywords
sod
gtpase
protein
sod1
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002634670A
Other languages
English (en)
French (fr)
Inventor
John F. Engelhardt
Weihong Zhou
Maged M. Harraz
Jennifer J. Marden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2634670A1 publication Critical patent/CA2634670A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C07K14/4706—Guanosine triphosphatase activating protein, GAP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90283—Oxidoreductases (1.) acting on superoxide radicals as acceptor (1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
CA002634670A 2005-12-30 2006-12-28 Method of identifying compounds useful to treat neuronal degenerative diseases Abandoned CA2634670A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75533705P 2005-12-30 2005-12-30
US60/755,337 2005-12-30
PCT/US2006/049424 WO2007079141A2 (en) 2005-12-30 2006-12-28 Method of identifying compounds useful to treat neuronal degenerative diseases

Publications (1)

Publication Number Publication Date
CA2634670A1 true CA2634670A1 (en) 2007-07-12

Family

ID=38134984

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002634670A Abandoned CA2634670A1 (en) 2005-12-30 2006-12-28 Method of identifying compounds useful to treat neuronal degenerative diseases

Country Status (6)

Country Link
US (3) US20070265350A1 (enExample)
EP (1) EP1971867A2 (enExample)
JP (1) JP2009521928A (enExample)
AU (1) AU2006332728A1 (enExample)
CA (1) CA2634670A1 (enExample)
WO (1) WO2007079141A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241622B2 (en) 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
EP1971867A2 (en) * 2005-12-30 2008-09-24 University of Iowa Research Foundation Method of identifying compounds useful to treat neuronal degenerative diseases
EP2970873A4 (en) * 2013-03-14 2017-02-22 President and Fellows of Harvard College Methods for selecting microbes from a genetically modified library to detect and optimize the production of metabolites
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
WO2017155973A1 (en) 2016-03-07 2017-09-14 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
KR20200088856A (ko) * 2017-11-15 2020-07-23 벤더르빌트 유니버시티 리소좀 기능의 개선 및 퇴행성 신경 질환의 치료를 위한 방법 및 조성물
EP4724816A2 (en) * 2023-06-06 2026-04-15 Mclaughlin Research Institute for Biomedical Sciences Methods for detecting the presence of at least one misfolded form of sod1 in a biological sample

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083713A (en) * 1992-08-31 2000-07-04 Bristol-Myers Squibb Company Cloning and expression of βAPP-C100 receptor (C100-R)
US5939460A (en) * 1996-07-08 1999-08-17 Idun Pharmaceuticals, Inc. Method of inhibiting NADPH oxidase
IL128017A0 (en) * 1998-07-22 1999-11-30 Technion Res & Dev Foundation Method for detecting protein-protein interactions and a kit therefor
ES2140354B1 (es) * 1998-08-03 2000-11-01 S A L V A T Lab Sa Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2.
EP1131425A2 (en) * 1998-11-18 2001-09-12 Incyte Pharmaceuticals, Inc. Inflammation-associated genes
CA2270795A1 (en) 1999-05-05 2000-11-05 Gestilab Inc. Neuroprotective compositions and uses thereof
US6492429B1 (en) * 2000-07-10 2002-12-10 N.V. Nutricia Composition for the treatment of osteoarthritis
US6485950B1 (en) * 2000-07-14 2002-11-26 Council Of Scientific And Industrial Research Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions
WO2003006614A2 (en) * 2001-07-12 2003-01-23 Exelixis, Inc. UBE2s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
JP2003201255A (ja) * 2001-11-05 2003-07-18 Otsuka Pharmaceut Factory Inc アルツハイマー病予防および治療剤
WO2003087399A1 (en) * 2002-04-17 2003-10-23 Glucox Ab Nad)p)h oxidase inhibitors for increased glucose uptake and treatment of type ii diabetes
WO2004047772A2 (en) * 2002-11-26 2004-06-10 Florida Atlantic University Catalytic antioxidants and methods of use
KR100522188B1 (ko) 2003-01-20 2005-10-18 주식회사 뉴로테크 뉴로트로핀에 의해 유도되는 세포괴사 억제 방법
US7067659B2 (en) * 2004-04-23 2006-06-27 Duke University Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
EP1602926A1 (en) * 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
US20060002913A1 (en) * 2004-06-22 2006-01-05 Gehlsen Kurt R Use of histamine and related compounds to treat disorders affecting muscle function
EP1971867A2 (en) * 2005-12-30 2008-09-24 University of Iowa Research Foundation Method of identifying compounds useful to treat neuronal degenerative diseases

Also Published As

Publication number Publication date
US20090239243A1 (en) 2009-09-24
US20080206792A1 (en) 2008-08-28
AU2006332728A1 (en) 2007-07-12
WO2007079141A9 (en) 2007-08-30
JP2009521928A (ja) 2009-06-11
WO2007079141A2 (en) 2007-07-12
EP1971867A2 (en) 2008-09-24
WO2007079141A3 (en) 2008-01-31
US20070265350A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
Zhang et al. Prolonged hypoxia alleviates prolyl hydroxylation-mediated suppression of RIPK1 to promote necroptosis and inflammation
US20080206792A1 (en) Method of identifying compounds useful to treat neuronal degenerative diseases
Zhang et al. The zinc transporter ZIP7 (Slc39a7) controls myocardial reperfusion injury by regulating mitophagy
US10105420B2 (en) Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
S. Hernandes et al. NADPH oxidase and neurodegeneration
EP2039367B1 (en) Prophylactic/therapeutic agent for neurodegenerative disease
US20080261201A1 (en) Methods and compounds to alter virus infection
KR20090048382A (ko) Ａｉｍｐ2-ｄｘ2의 억제제를 유효성분으로 포함하는 염증성질환 예방 및 치료용 조성물
Wu et al. Protease Omi cleaving Hax-1 protein contributes to OGD/R-induced mitochondrial damage in neuroblastoma N2a cells and cerebral injury in MCAO mice
Laedermann et al. Ubiquitylation of voltage-gated sodium channels
US7491501B2 (en) Methods for identifying modulators of intracellular aggregate formation
US9766241B2 (en) PGC-1beta-protein-function regulator, mitochondria-function regulator, anti-obesity agent, and screening method therefor
US20160031955A1 (en) Methods for Treating Mitochondrial Disorders and Neurodegenerative Disorders
WO2020112565A1 (en) Antagonists of mitofusion 1 and beta ii pkc association for treating heart failure
KR101943706B1 (ko) 유비퀴틴 활성 저해용 조성물
JAQUET " Identification of pharmacological inhibitors of NADPH oxidases for the treatment of oxidative stress-derived pathologies
Zhao et al. OTUD6A drives dopaminergic neuronal degeneration of Parkinson’s disease through deubiquitinating ACTG1 in neuronal cells
Wang et al. HDAC6 Inhibition Rescues Oxidative Stress-derived Neuronal Apoptosis Following Intracerebral Hemorrhage Via MDH1 Acetylation
Antoniel The unique histidine of F-ATP synthase subunit OSCP mediates regulation of the permeability transition by matrix pH
US20100113557A1 (en) Method for prevention of tumor
Warr Regulation of LASU1-mediated Mcl-1 Degradation and its Roles in Apoptosis
Raschke Mammalian m-AAA Proteases as key regulators of mitochondrial function: analysis of dominant negative mutant variants
JP2009538124A (ja) スクリーニング方法
KR20090081884A (ko) 백스 인히비터-1을 유효성분으로 포함하는 ｅｒ-스트레스매개 질환의 예방 및 치료용 조성물
Eichelbaum et al. MAMMALIAN PEPTIDE TRANSPORTERS AS TARGETS FOR DRUG DELIVERY

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160817